NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma
NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma is a paper indexed in ScholarIQ from OpenAlex.
How many citations does NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma have?
NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma has 852 citations in the OpenAlex counts ScholarIQ stores.
When was NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma published?
NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma has 2015 year in the ScholarIQ index.
What is the open-access status of NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma?
NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma has green oa status in the ScholarIQ index.
What is the DOI of NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma?
The DOI for NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma is on the source record.
What is the PMID of NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma?
The PMID for NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma is on the source record.
What is the OpenAlex record for NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma?
The OpenAlex for NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma is on the source record.